{'fraction_non_alphanumeric': 0.023183925811437404, 'fraction_numerical': 0.010819165378670788, 'mean_word_length': 6.280898876404494, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of cardiac medications on ventricular function in patients with Duchenne muscular dystrophy–related cardiomyopathy

The DMD Care Considerations Working Group Guidelines 2010 recommended treating cardiac dystrophinopathy with angiotensin‐converting enzyme‐inhibitor (ACEi) and beta‐blocker (BB) therapy to prevent the progressive decline in left ventricular function expected from earlier, natural history studies. The aim of this research was to audit change in measures of left ventricular function over 8 years to 4 years before and 4 years after deploying an ACEi/BB combination systematically at a dedicated “cardiology‐muscle” clinic.